The owner of a high-profile development site in Newark — where city officials have approved plans for more than 2,400 new residential units — has put the property on the market.
A biopharmaceutical company has sold the site of its headquarters in Newark, a well-known office tower spanning nearly 500,000 square feet, in a deal valued at more than $49 million.
